In-vitro Fertilization Market Size & Share 2024 to 2032

In-vitro Fertilization Market Size

In-vitro Fertilization Market size was valued at USD 20.2 billion in 2023 and is set to register growth at a 5.7% CAGR between 2024 and 2032. The growth of the market is primarily driven by increasing infertility rates.

According to the World Health Organization (WHO), about 186 million individuals worldwide live with infertility. Additionally, conditions such as polycystic ovary syndrome (PCOS) and endometriosis, which affect 1 in 10 women globally, are contributing to the rising demand for IVF.
 

Another significant growth driver is delayed parenthood and an aging population. According to CDC data, the birth rate among women aged 40 to 44 years rose by 4% in 2022. Fertility naturally declines with age, particularly after 35, leading to increased reliance on Assisted Reproductive Technology (ART), including IVF, for conception. The American Society for Reproductive Medicine reports that women over 35 account for more than 40% of ART cycles. Thus, as the age of pregnancy increases, the demand for procedures such as IVF will escalate, driving market growth.
 

In-vitro fertilization is a medical procedure used to assist with conception by fertilizing an egg in a laboratory setting—outside the human body—and then transferring the resultant embryo into the woman's uterus. It is one of the most common and effective forms of Assisted Reproductive Technology (ART), used to treat various infertility issues, including ovulation disorders, blocked or damaged fallopian tubes, and male infertility.
 

In-vitro Fertilization Market Trends

• The increasing number of infertility cases is a significant driver of the market.
   
• For instance, according to the WHO, 1 in 6 people globally suffers from infertility, indicating a high need for appropriate fertility care.
   
• Technological advancements have significantly improved IVF success rates. For example, the success rate of IVF has increased from around 10% in the 1980s to approximately 30-35% per cycle in 2023, depending on the age of the woman.
   
• Time-lapse imaging technology allows embryologists to monitor embryo development more closely, improving selection and implantation success rates. This technology has contributed to the overall increase in IVF success rates.
   
• Additionally, IVF is becoming more culturally accepted in many parts of the world. For instance, countries in the Middle East and Asia, where assisted reproductive technology was once stigmatized, are now seeing significant growth in IVF usage.
   

In-vitro Fertilization Market Analysis

Based on product, the market is segmented into equipment, reagents & media, and accessories. The equipment segment, which dominated the market in 2023 and accounted for USD 9.4 billion, is further bifurcated into microscope, imaging system, sperm analyzer system, ovum aspiration pump, micromanipulator system, incubator, gas analyzer, cryosystem, laser system, sperm separation system, cabinet, anti-vibration table, witness system, and other equipment.
 

• IVF equipment is typically expensive, contributing to a larger market share. Items including incubators, micromanipulators, cryopreservation units, and imaging systems require significant investment, and the cost of maintaining and upgrading these machines adds to the overall expenditure.
   
• Moreover, compliance with strict regulatory standards for fertility clinics and laboratories necessitates the use of high-quality equipment. Regulations often mandate specific types of equipment to ensure safety, accuracy, and reliability in IVF procedures, further increasing the demand for compliant and high-performance equipment.

Learn more about the key segments shaping this market

Download Free PDF

Based on the type of cycle, the IVF market is segmented into fresh non-donors, frozen non-donors, frozen donors, and fresh donors. The fresh non-donors segment dominated the market in 2023, with a market share of 48.1%.
 

• The success rate is higher in the case of fresh non-donor cycles. In this type of cycle, a woman’s own eggs are used immediately after retrieval, resulting in higher success rates compared to other types of cycles. This is because the eggs are fresh and have not been subjected to the freezing and thawing process, which can potentially damage them or reduce their quality.
   
• Fresh non-donor cycles tend to be less expensive than cycles involving donor eggs. The cost of acquiring and compensating an egg donor, along with additional legal and medical processes, makes donor cycles more expensive, thereby increasing the preference for fresh non-donor cycles.
   
• In many fertility clinics, fresh non-donor cycles are the standard initial approach for patients undergoing IVF, particularly for those who have not been diagnosed with severe ovarian issues. Clinics often recommend this as the first option before considering alternatives like frozen embryo transfers (FET) or donor eggs. These factors contribute to overall market growth.
   

Based on procedure, the in-vitro fertilization market is segmented into conventional IVF, IVF with intracytoplasmic sperm injection (ICSI), minimal IVF, IVF with donor eggs, and other procedures. The conventional IVF segment dominated the market in 2023 and is expected to witness growth at a CAGR of 5.4%.
 

• Conventional IVF typically has higher success rates compared to other forms of IVF, such as natural cycle IVF or mini-IVF. This is because conventional IVF involves stimulating the ovaries to produce multiple eggs, increasing the chances of successful fertilization and embryo development.
   
• Conventional IVF can be effective for a wide range of fertility issues, including male factor infertility, tubal blockages, and unexplained infertility, making it a versatile option.
   
• Conventional IVF is a well-established and widely studied procedure with decades of clinical experience, making it a trusted and reliable option for many fertility specialists and patients. These factors contribute to the segment’s growth.
   

Based on end-use, the in-vitro fertilization market is bifurcated into fertility clinics and IVF centers, hospitals & surgical centers, research institutes, and cryobanks. The fertility clinics and IVF centers segment is anticipated to reach USD 18.7 billion by 2032.
 

• Fertility clinics and IVF centers are highly preferred by patients due to the presence of experts, including reproductive endocrinologists, embryologists, and fertility nurses, who are highly trained in IVF and other fertility treatments at these settings.
   
• Fertility clinics are equipped with state-of-the-art technology specifically designed for assisted reproductive procedures, which might not be available in general hospitals.
   
• Fertility clinics may offer more flexible payment options and packages tailored to fertility treatments, which can be more cost-effective for patients compared to the broader services offered by hospitals. These factors result in a high adoption rate.

North America dominated the global in-vitro fertilization market in 2023 with a revenue of USD 6.2 billion and is anticipated to reach USD 9.8 billion by 2032.
 

• North America is known for its innovative medical technology and innovation. Fertility clinics in this region have access to the latest advancements in reproductive medicine, making IVF a widely available and effective option.
   
• Many couples in North America face fertility challenges due to factors such as delayed childbearing, lifestyle choices, and underlying health conditions. As more individuals and couples delay having children for career or personal reasons, the demand for fertility treatments like IVF has increased.
   
• In some parts of North America, particularly in certain states and provinces, insurance coverage for IVF is available, making it more accessible to a broader population. Additionally, various financing options and payment plans offered by fertility clinics help make IVF treatments more affordable.
   

The U.S. in-vitro fertilization market was valued at USD 5.9 billion in 2023.
 

• IVF is one of the most common forms of assisted reproductive technology (ART) used in the U.S. Due to factors like delayed childbearing, increased awareness, and the rising prevalence of infertility issues, the demand for IVF has grown significantly.
   
• The U.S. is home to some of the most advanced fertility clinics in the world, offering innovative technologies such as preimplantation genetic testing (PGT), egg freezing, and embryo selection.
   
• Insurance coverage for IVF varies widely across the U.S. Some states mandate insurance coverage for fertility treatments, which positively affects market growth.
   

Germany is anticipated to witness robust growth in the global in-vitro fertilization market.
 

• Germany has seen a trend of couples delaying childbearing due to career, education, or personal reasons. As women age, fertility naturally declines, leading to a higher demand for IVF treatments.
   
• Factors such as stress, unhealthy diets, smoking, and environmental pollutants contribute to rising infertility rates, which in turn drive the demand for assisted reproductive technologies (ART) like IVF.
   
• Additionally, Germany is known for its advanced healthcare system and technological innovation. The development and adoption of new reproductive technologies, such as preimplantation genetic testing (PGT), time-lapse imaging of embryos, and improved cryopreservation techniques, have made IVF more effective and attractive to prospective parents.
   

The Asia Pacific region is anticipated to witness high growth in the in-vitro fertilization market, growing at a CAGR of 7% over the analysis years.
 

• Similar to global trends, couples in the Asia-Pacific region are increasingly delaying childbearing due to career, education, and personal reasons. This delay, particularly among women, contributes to higher infertility rates and drives the demand for IVF services.
   
• The Asia-Pacific region has become a hub for medical tourism, with countries like India, Thailand, Malaysia, and Singapore attracting international patients seeking affordable and high-quality IVF treatments. Lower costs, coupled with advanced medical care, make these countries popular destinations for fertility treatment.
   
• Japan and South Korea have aging populations and declining birth rates, leading to strong government support for IVF and other fertility treatments.
   

In-vitro Fertilization Market Share

The competitive landscape in the market is dynamic and highly competitive. Major players, such as The Cooper Companies Inc. and Thermo Fisher Scientific Inc. dominate the market due to their strong brand presence and supply of essential equipment, diagnostic tools, and consumables for IVF procedures. Start-ups and smaller firms are innovating with technologies such as AI-based embryo selection (e.g., Embryonics), digital health platforms for fertility tracking (e.g., Kindbody), and niche services like egg freezing and fertility preservation, further reshaping the market.
 

In-vitro Fertilization Market Companies

Prominent players operating in the in-vitro fertilization industry include:

• Cook Medical
• Esco Medical
• FUJIFILM Irvine Scientific, Inc.
• GE HealthCare Technologies, Inc.
• Genea BIOMEDX
• Gynemed GmBH & Co. KG
• Hamilton Thorne Ltd.
• IVFtech ApS
• Kitazato Corporation
• Merck KGaA
• Nidacon International AB
• The Baker Company Inc.
• The Cooper Companies Inc.
• Thermo Fisher Scientific Inc.
• Vitrolife Group
   

In-vitro fertilization Industry News:

• In October 2023, Hamilton Thorne acquired Gynetics Medical Products N.V. This acquisition aimed to strengthen the company’s consumables segment, which is used in the development of assisted reproductive technology products. The strategy also helped Hamilton Thorne expand its footprint in the European market.
   

The in-vitro fertilization market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Equipment
  • Microscope
  • Imaging system
  • Sperm analyzer system
  • Ovum aspiration pump
  • Micromanipulator system
  • Incubator
  • Gas analyzer
  • Cryosystem
  • Laser system
  • Sperm separation system
  • Cabinet
  • Anti-vibration table
  • Witness system
  • Other equipment 
• Reagents & media
  • Embryo culture media
  • Cryopreservation media
  • Sperm processing media
  • Ovum processing media
• Accessories

Market, By Type of Cycle

• Fresh non-donors
• Frozen non-donors
• Frozen donors
• Fresh donors

Market, By Procedure

• Conventional IVF
• IVF with intracytoplasmic sperm injections
• Minimal IVF
• IVF with donor eggs
• Other procedures

Market, By End-use

• Fertility clinics and IVF centers
• Hospitals & surgical centers
• Research institutes
• Cryobanks

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa